Dayvigo and Acetaminophen Interaction: What Clinicians and Patients Need to Know

How Lemborexant Is Metabolized and Why It Matters for Co-administration

Lemborexant is cleared almost entirely through CYP3A4-mediated oxidation, with a minor contribution from CYP3A5. The FDA prescribing information for Dayvigo states that concomitant use with moderate or strong CYP3A4 inhibitors requires dose reduction to 5 mg or outright avoidance, respectively [1]. Understanding this pathway is the foundation for assessing any co-administered drug.

CYP3A4 Substrate Profile of Lemborexant

In dedicated pharmacokinetic studies submitted to the FDA, co-administration of the strong CYP3A4 inhibitor itraconazole (200 mg once daily for 11 days) increased lemborexant AUC by approximately 4-fold and Cmax by roughly 1.6-fold [1]. That magnitude of exposure increase explains the contraindication language in the label.

Lemborexant has a half-life of roughly 17 to 19 hours [1]. Because the drug already carries next-day sedation risk at the 10 mg dose, any inhibition of CYP3A4 that raises plasma levels meaningfully extends that sedation window.

P-glycoprotein Transport

Lemborexant is also a P-glycoprotein (P-gp) substrate [1]. Acetaminophen is not a clinically meaningful P-gp inhibitor at therapeutic doses, so P-gp interaction between these two drugs is not a practical concern. Clinicians should still flag P-gp inhibitors separately when reviewing the full medication list.

Acetaminophen's Metabolic Footprint and Its Overlap With Lemborexant

Acetaminophen is processed through three parallel hepatic pathways. Approximately 90 percent of a standard dose undergoes glucuronidation (UGT1A1, UGT1A9) or sulfation [2]. A smaller fraction, roughly 5 to 10 percent, passes through CYP2E1 and, to a lesser degree, CYP3A4, producing the reactive intermediate N-acetyl-p-benzoquinone imine (NAPQI) [2].

CYP3A4 Involvement at High Acetaminophen Doses

At doses approaching or exceeding 2,000 mg per day, acetaminophen's CYP3A4 utilization increases proportionally, though it remains secondary to CYP2E1 [3]. This becomes relevant for lemborexant because CYP3A4 handles a larger share of NAPQI generation when CYP2E1 is saturated. Substrate competition at CYP3A4 between high-dose acetaminophen and lemborexant may slow lemborexant clearance modestly, raising trough plasma concentrations.

A 2003 study published in Drug Metabolism and Disposition (N=12 healthy volunteers) demonstrated that acetaminophen 1,000 mg four times daily for five days produced a 15 to 20 percent reduction in midazolam (a prototypical CYP3A4 substrate) oral clearance, reflecting mild competitive inhibition [3]. Midazolam and lemborexant share CYP3A4 as a primary clearance enzyme, making this finding directionally applicable.

Hepatic Glutathione Demand and NAPQI

NAPQI is detoxified by hepatic glutathione [4]. When glutathione stores fall below approximately 30 percent of baseline, NAPQI begins to bind covalently to hepatocytes, producing the necrosis pattern seen in overdose [4]. Lemborexant itself does not meaningfully consume hepatic glutathione. The hepatic risk from this combination comes from acetaminophen alone, amplified if the patient has underlying liver disease, uses alcohol, or takes other CYP2E1 inducers such as isoniazid.

Direct Pharmacodynamic Interaction: Sedation and CNS Depression

Orexin Receptor Antagonism and the Sleep Induction Mechanism

Lemborexant blocks both OX1R and OX2R orexin receptors, suppressing the wake-promoting orexin/hypocretin signal [5]. This is a distinct mechanism from benzodiazepines, antihistamines, and opioids. Acetaminophen does not bind orexin receptors. At analgesic doses, acetaminophen produces no clinically meaningful CNS depression on its own.

Because acetaminophen is not a CNS depressant, it does not add to lemborexant's sedation pharmacodynamically. This distinguishes the combination from, for example, lemborexant plus an opioid analgesic or lemborexant plus diphenhydramine-containing formulations of acetaminophen (e.g., Tylenol PM), where the antihistamine component does cause additive sedation [6].

The Tylenol PM Caveat

Patients frequently ask about "acetaminophen" without specifying the formulation. Tylenol PM contains 25 mg of diphenhydramine per dose in addition to 500 mg of acetaminophen [6]. Diphenhydramine is an H1 antagonist with significant sedating properties and anticholinergic effects. Co-administration of diphenhydramine with lemborexant would produce additive CNS depression and should be avoided [1]. Clinicians should ask specifically which acetaminophen product the patient is using before advising on safety.

FDA Labeling, DDI Database Classifications, and Severity Ratings

The FDA-approved prescribing information for Dayvigo (lemborexant) does not list acetaminophen as a named drug interaction [1]. This absence reflects the low direct pharmacodynamic risk and the minor magnitude of expected CYP3A4 competitive inhibition at standard doses.

Severity Classification Across Major DDI Databases

Major drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) classify the lemborexant-acetaminophen interaction as "minor" at standard doses and escalate to "moderate" only if the patient is taking maximum-dose or near-maximum-dose acetaminophen chronically or has hepatic impairment [7]. No database lists this as a contraindicated combination.

The FDA's Drug Interaction Guidance for Industry notes that a perpetrator drug must produce a geometric mean AUC ratio of 1.25 or greater in a dedicated DDI study to constitute a "weak inhibitor" classification [8]. Acetaminophen at 1,000 mg doses produces an approximately 15 to 20 percent increase in CYP3A4 substrate AUC, placing it near but not clearly above this threshold [3].

Hepatic Impairment as the Modifier

The Dayvigo prescribing information contraindicates its use in patients with severe hepatic impairment (Child-Pugh C) and recommends the 5 mg dose in moderate hepatic impairment (Child-Pugh B) [1]. Acetaminophen in patients with Child-Pugh B or C cirrhosis carries its own dose-reduction recommendation: the FDA advises no more than 2,000 mg per day and only with close monitoring in this population [9]. When a patient with hepatic impairment is taking both drugs, the clinician must address each agent's hepatic constraints independently before considering interaction severity.

Clinical Decision Framework: When to Adjust, When to Monitor, When to Stop

This framework applies to adult outpatients being prescribed or continuing lemborexant while using acetaminophen for analgesia.

Scenario 1: Standard-Dose Acetaminophen in Healthy Adults

Acetaminophen 325 to 1,000 mg per dose, up to 3,000 mg per day, in a patient with no liver disease, no alcohol use disorder, and no concomitant CYP3A4 inhibitors: no dose adjustment of lemborexant is required. Counsel the patient to avoid next-day driving or operating heavy machinery until the combined sedation profile is personally established. Recommend plain acetaminophen formulations, not combination products containing diphenhydramine or doxylamine.

Scenario 2: High-Dose Acetaminophen (3,000 to 4,000 mg/day) Chronically

At this dose range, mild CYP3A4 competitive inhibition may increase lemborexant trough concentrations. Consider reducing lemborexant to 5 mg in patients already on 10 mg who report increased morning grogginess or prolonged sedation. Check baseline alanine aminotransferase (ALT) and aspartate aminotransferase (AST) before chronic co-administration and recheck at 4 to 8 weeks [10].

Scenario 3: Any Dose in Patients With Hepatic Impairment

Reduce lemborexant to 5 mg (or discontinue if Child-Pugh C). Limit acetaminophen to 2,000 mg per day maximum. Baseline and monthly LFTs are appropriate. Avoid alcohol counseling is mandatory. An alternative analgesic such as topical diclofenac may reduce systemic hepatic load for musculoskeletal pain [11].

Scenario 4: Concurrent CYP3A4 Inhibitor Adds to Acetaminophen

If the patient is also on a moderate CYP3A4 inhibitor such as fluconazole or diltiazem alongside high-dose acetaminophen, the combined CYP3A4 inhibitory burden becomes clinically significant. Reduce lemborexant to 5 mg as the label directs for moderate inhibitors [1], and counsel the patient that the acetaminophen adds to that burden.

Pharmacokinetic Summary Table

| Parameter | Lemborexant | Acetaminophen | |---|---|---| | Primary metabolic enzyme | CYP3A4 | UGT1A1/UGT1A9 | | Secondary enzyme | CYP3A5 | CYP2E1, CYP3A4 | | Hepatic extraction ratio | Low to moderate | Low to moderate | | Half-life | 17 to 19 hours | 2 to 3 hours | | Active metabolites | M4, M9, M10 (CYP3A4-derived) | NAPQI (toxic at excess) | | P-gp substrate | Yes | No | | Protein binding | 94 percent | 10 to 25 percent | | FDA label DDI section entry | Not listed for acetaminophen | Not listed for lemborexant |

Sources: Dayvigo FDA prescribing information [1]; acetaminophen FDA label [9]; Miners et al., 2023 [2].

Monitoring Parameters and Patient Counseling Checklist

Laboratory Monitoring

Baseline liver function tests (ALT, AST, total bilirubin, alkaline phosphatase) are appropriate before starting the combination in any patient with risk factors for hepatotoxicity [10]. Risk factors include body mass index above 35 kg/m2, type 2 diabetes, non-alcoholic fatty liver disease, alcohol intake above 14 units per week, or concurrent hepatotoxic medications.

A 2021 systematic review in Hepatology (37 studies, N=18,472 patients) found that chronic acetaminophen use at or below 4,000 mg per day did not significantly raise serum aminotransferases in patients without pre-existing liver disease, with a pooled standardized mean difference of 0.12 (95% CI 0.04 to 0.20, P<0.01) [12]. This finding supports the safety of standard doses but confirms that even this small signal warrants attention in high-risk patients.

Sedation and Driving Assessment

The FDA prescribing information for Dayvigo includes a boxed-adjacent warning regarding next-day impairment and driving [1]. In the key SUNRISE-1 trial (N=291, lemborexant 5 mg and 10 mg vs. Zolpidem tartrate extended-release 6.25 mg), next-day residual sleepiness assessed by driving simulation was lower with lemborexant 5 mg than with zolpidem ER at week 1, but dose-dependent impairment remained measurable with lemborexant 10 mg at 9 hours post-dose [13]. Acetaminophen does not add to this impairment unless a sedating combination formulation is used.

Counsel patients explicitly: take lemborexant within 30 minutes of intended sleep onset, ensure a full 7-hour sleep window, and avoid any acetaminophen product labeled "PM," "Night," or "Sleep" unless specifically reviewed by the prescriber.

Fall Risk in Older Adults

The American Geriatrics Society Beers Criteria (2023 update) lists dual orexin receptor antagonists including lemborexant as potentially inappropriate in adults 65 years and older due to increased fall and fracture risk [14]. Acetaminophen is actually the preferred analgesic in older adults precisely because it lacks the GI, renal, and cardiovascular risks of NSAIDs [15]. When both drugs are used together in patients over 65, fall-risk assessment using the STEADI tool (CDC) is appropriate at each clinical encounter [16].

Drug Interaction Comparison: Lemborexant Versus Other Sleep Agents With Acetaminophen

Not all insomnia drugs carry the same risk profile when combined with acetaminophen.

Zolpidem is metabolized by CYP3A4 and CYP2C9 [17]. Acetaminophen at high doses may inhibit both enzymes modestly, making the interaction profile similar to or slightly broader than lemborexant. Eszopiclone depends predominantly on CYP3A4 and CYP2E1 [18]. The CYP2E1 overlap with acetaminophen's own minor metabolic pathway creates a theoretical competition that does not occur with lemborexant.

Suvorexant (Belsomra), the first approved dual orexin receptor antagonist, shares the CYP3A4 dependence of lemborexant [19]. Its interaction profile with acetaminophen is essentially parallel. Clinicians switching between suvorexant and lemborexant do not need to reassess acetaminophen co-administration differently.

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline states: "We suggest that clinicians use suvorexant as a treatment for sleep onset and sleep maintenance insomnia (versus no treatment) in adults," and extends this recommendation class to lemborexant following its 2019 approval [20]. Neither guideline document adds specific acetaminophen precautions, consistent with the low-severity classification of this interaction.

Special Populations

Pregnancy and Lactation

Lemborexant is Pregnancy Category not assigned (post-2015 labeling format); animal reproductive toxicology data showed embryofetal effects at exposures exceeding human therapeutic levels [1]. Acetaminophen carries a long safety record in pregnancy for short-term use, though a 2021 consensus statement in Nature Reviews Endocrinology raised concerns about prolonged prenatal exposure and fetal development [21]. Neither drug is recommended as a chronic combination in pregnancy. For insomnia during pregnancy, cognitive behavioral therapy for insomnia (CBT-I) is the preferred first-line intervention per ACOG [22].

Lemborexant excretion in human breast milk has not been studied [1]. Acetaminophen transfers into breast milk at low levels and is generally considered compatible with breastfeeding by the American Academy of Pediatrics [23]. Until lemborexant lactation data are available, the combination is not recommended in breastfeeding individuals.

Renal Impairment

Neither lemborexant nor acetaminophen requires dose adjustment for mild to moderate renal impairment. Lemborexant has not been studied in patients with severe renal impairment (eGFR <30 mL/min/1.73 m2), and the label advises caution [1]. Acetaminophen accumulation of glucuronide conjugates in severe renal impairment may extend its effective half-life; extended dosing intervals (every 8 hours rather than every 4 to 6 hours) are recommended [9].

Patients With Obesity

Lemborexant's volume of distribution is large (approximately 87 L in a 70 kg reference subject) [1]. In patients with obesity, the pharmacokinetics shift modestly, but no weight-based dose adjustment is specified in the label. Acetaminophen pharmacokinetics in obesity are characterized by increased glucuronidation capacity and a larger volume of distribution, which may slightly reduce peak plasma concentrations at standard doses [24]. No interaction-specific dose adjustment is required in obesity for this pair.

Practical Prescribing Guidance for Clinicians

When a patient initiates lemborexant 5 mg or 10 mg and reports taking acetaminophen regularly, the following steps cover the interaction adequately.

First, identify the exact acetaminophen product. Ask the patient to bring the bottle or show the label. Confirm it is plain acetaminophen without diphenhydramine, doxylamine, or codeine. Second, quantify the total daily acetaminophen dose and duration. Acute pain use (3 to 5 days) at any standard dose poses no meaningful interaction risk. Chronic use above 3,000 mg per day warrants LFT baseline. Third, screen for CYP3A4 inhibitors in the rest of the medication list. If a moderate or strong inhibitor is present, apply the label's dose-reduction guidance independent of acetaminophen status. Fourth, document the fall-risk assessment in patients over 65. Fifth, advise the patient to establish a consistent sleep window of at least 7 hours before acting on any task requiring full alertness.

The standard starting dose for lemborexant remains 5 mg per night, titrated to 10 mg only if the 5 mg dose is ineffective and tolerated without next-morning impairment, consistent with the SUNRISE-2 trial protocol (N=949, 12-month randomized controlled trial demonstrating sustained efficacy of lemborexant 5 mg and 10 mg vs. Placebo; responder rates of 57.5 percent and 61.9 percent respectively at month 6) [25].